OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-03-31-accounts

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Charity number: 1082702

TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

THE UK MYELOMA SOCIETY

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

CONTENTS

Page
Reference and Administrative Details of the Charity, its Trustees and Advisers 1
Trustees' Report 2 - 8
Independent Examiner's Report 9
Statement of Financial Activities 10
Balance Sheet 11
Notes to the Financial Statements 12 - 21

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Trustees' Annual Re ort for the eriod p p

Period start date Period end date Day Month Year Day Month Year From 1 April 2023 To 31 March 2024

Section A Reference and administration details

Charity name UK Myeloma Society Other names charity is known by UKMS Registered charity number (if any) 1082702 Charity's principal address Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield Postcode WF1 4DG

Names of the charity trustees who manage the charity

1.
2.
3.
4.
5.
6.
7.
8.
9.		 Trustee name Office (if any) Dates acted if not for whole year Name of
person (or
body)
entitled to
appoint
trustee (if
any)
Dr Ceri Bygrave
(Cardiff)		 Chair from November 2023
Wales Representative		 November 2023 – November 2025
Dr Neil Rabin
(London)		 Past Chair November 2023 – November 2025
Dr John Ashcroft
(Leeds, Mid Yorks)		 Teasurer November 2023 – November 2026
Dr Matthew Jenner
(Southampton)		 Secretary November 2023 - November 2026
Dr Rachel Hall
(Bournemouth)		 Chair Elect November 2023 -November 2025
Dr Jonathan Sive
(London)		 Education Lead January 2023 -January 2026
Prof Gordon Cook
(Leeds)		 Dean of College of Myeloma November 2019- on going
Prof Guy Pratt
(Birmingham)		 Board member November 2023-November 2026
Prof Martin Kaiser
(London)		 Board member January 2022 – January 2025

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

10.
11.
12.
13.
14.
15.
16.
17.
18.
19.		 Dr Karthik
Ramasamy
(Oxford)		 Communications Lead June 2022 - June 2025
Dr Simon Stern
(Surrey)		 Guidelines Secretary June 2020 - November 2024
Dr Rakesh Popat
(London)		 Science Lead November 2021 - November 2024
Jackie Quinn
(Belfast)		 Myeloma Nurse Lead November 2023 -November 2025
Dr Sarah Lawless
(N.Ireland)		 N.Ireland Representative
(Invited Board member)		 January 2021 -January 2024
Dr Jennifer Travers
(Glasgow)		 Scotland Representative
(Invited Board member)		 November 2023- November 2026
Dr Shelly Lawson
(Sheffield)		 Board member November 2023 – November 2026
Catherine Loughran
(Leicester)		 Board member
Pharmacylead		 November 2023-November 2025
Dr Sally Moore
(Bath)		 Board member November 2023-November 2026
Sophie Castell
(Myeloma UK)		 Patient/Charity
Representative		 January 2018-ongoing

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Names and addresses of advisers (Optional information) Names and addresses of advisers (Optional information) Names and addresses of advisers (Optional information)
Type of adviser
Name
Address
Independent Examiner Menzies LLP Menzies LLP, Richmond House
Walkern road, Stevenage, Herts, SG1 3QP
Bankers Coutts & Co 440 Strand, London, WC2R 0QS
Name of chief executive or names of senior staff members (Optional information)

Section B Structure, governance and management

Description of the charity’s trusts

Type of governing document Constitution (eg. trust deed, constitution)

How the charity is constituted Association (eg. trust, association, company)

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Trustee selection methods

Elected from membership

Additional governance issues (Optional information)

You may choose to include additional information, where relevant, about:

Section C Objectives and activities

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

Summary of the main The UKMS had a further active year in pursuit of its’ charitable objectives which activities undertaken for the are, education, research and advocacy. public benefit in relation to To that end three Executive Committee meetings were held 2023; March, June and these objects (include within November. this section the statutory declaration that trustees have In keeping with our objectives we have made significant progress in a number of key had regard to the guidance areas including educational meetings, guidelines and advocacy. The main activities issued by the Charity undertaken to further its charitable purposes for the public benefit are detailed Commission on public benefit) within this report. There are summarised in the following pages.

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Additional details of objectives and activities (Optional information)

Revenue

You may choose to include further statements, where relevant, about:

•
Revenue received for corporate sponsorship contributed £123,800 (April 2023-
March 2024). This re-enforces the support by pharma for the work that the
UKMS undertakes. BMS supported the UKMS by awarding a corporate giving
grant of £3,000 in 2024. This ore grant was to support mission and objectives
received from Bristol Myers Squibb.
•
Separately, £33,000 was raised by Hartley Taylor Medical Communications Ltd
from pharma (GSK, J&J, Sanofi x £10k + Amgen £3k) to support for the
inaugural UKMRA Away Day on the 16-17 January 2024 in York.
•
In additional, £2,610 was raised from Pharma for the inaugural UKMS
Pharmacy Education Day on the 23 November 2023 at the Wellcome Collection
(Sanofi £500, Pfizer £1,500 and BMS £500 + £110 GSK).
Education
The Autumn Day was held on 9thNovember 2023, as a hybrid meeting at the
Cavendish Conference Centre and accessed on a virtual platform. The programme
theme was ‘Myeloma Management – Beyond the Drugs’and featured Professor
Heinz Ludwig from the Wilhelminen Cancer Research Institute in Vienna. He
presented the Michael Morley Lecture on ‘Managing infections in the new era of
myeloma therapies – prophylaxis, monitoring and treatment’.
The Spring Day was also a hybrid meeting and was held on 20thMarch 2024. The
theme for this meeting was the, ‘Controversies and Uncertainties – Unanswered
Questions in Myeloma’. The plenary lecture was given by Professor Niels van der
Donk from the Amsterdam University Medical Centre. His talk was entitled,
‘Bispecific Abs and CAR-T: sequencing, toxicities and practicalities’.
Travel Bursaries
A total of six travel bursaries for scientific conferences were awarded in 2023 to
winning abstracts.
•
2 x ASH San Diego £1,200 each
•
2 x EHA Frankfurt £900 each
•
2 X IMS Athens £900 each

The abstracts were presented at the subsequent Autumn / Spring Days in either November 2023 or March 2024. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e- newsletter.

Section D Achievements and performance

Summary of the main
achievements of the charity
during the year		 25 years of the UKMS November 2023-24
In November 2023, the Society began marking its 25 year anniversary. To
communicate this, a unique 25 year logo was created and used on all
communications throughout the year. A reception held at the Hope Street Hotel in
Liverpool for UKMS members, speakers and stakeholders during the BSH Annual
meeting on the 29 April 2024 where the Society was invited to host a joint
synposium. (Venue and Catering - £1,940).

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Section D Achievements and erformance p

Education: The annual meetings Production of two successful and well attended educational hybrid meetings in November 2023 and March 2024. For full programme details, please refer to the section above and the UKMS website. Travel Bursaries for scientific meetings

The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2023-24 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2023-24. Further details can be found Section C.

Advocacy

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients. Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting.

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 17[th] May 2023. On the 25 - 26 January 2024, the UKMRA held the first Away Day at the Principle Hotel in York. Around 30 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials.

Myeloma Nurse Group

Jackie Quinn took over as the Chair of the nurse group from Sarah Henshaw in November 2023.

Projects and discussion for the 2023 included;

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

Section D Achievements and erformance p

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 23 November 2023, the group held the first Annual Pharmacy Education Day at the Wellcome Collection in central London.

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2023 fellows : Professor Ray Powles CBE Dr Matthew Streetly Professor Philippe Moreau

Section E Financial review

The UKMS’s policy on its reserves is to maintain a sufficient level of funds to enable Brief statement of the charity’s operating activities to be supported, taking account of potential risks and policy on reserves contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially Not applicable in deficit Further financial review details (Optional information) Income You may choose to include • Education Grants from Corporate Sponsors contributed approximately £123,800 additional information, where in March 2023 - April 2024.

You may choose to include additional information, where relevant about:

The Michael Morley Fund This fund is from a patient’s estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

Expenditure

Educational meetings 2023-2024

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

UKMRA

Sponsorship raised £33,000 (GSK, J&J, Sanofi x £10k + Amgen £3k) Spend £16,055 Hartley Taylor Ltd fees £12,000 C/F to 2025 £4,945 Spend breakdown Travel £4,079 Venue £8,611 AV £2,510 HT travel & hotels £856

Travel Bursaries 2023

A total of six travel bursaries for scientific conferences were awarded in 2023 to winning abstracts.

Reserves

The UKMF’s reserves remain sound as of 31 March 2024 and were approximately £536,622 (2023: £498,189). The investment is held to generate investment income for use within the Charity along with cash used to continue the Charity activities.

Section F Other optional information ~~——~~

Section G Declaration

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s) ~~Dr dan tar |~~ Full name(s) Dr John Ashcroft Position (eg Secretary, Chair, Treasurer etc)

Date 30-Jan-2025

TAR

2023-2024

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2024

Independent Examiner's Report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2024.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: Dated: Stuart Cuzner ACA FCCA Menzies LLP Chartered Accountants Richmond House, Walkern Road Stevenage SG1 3QP

Page 9

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024

Note
Income from:
Donations and legacies
3
Investments
4
Total income
Expenditure on:
Raising funds
5
Charitable activities
7
Total expenditure
Net income before net gains/(losses) on investments
Net gains/(losses) on investments
12
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward		 Unrestricted
funds
2024
£
130,667
6,850
137,517
1,488
116,069
117,557
19,960
15,674
35,634
498,189
35,634
533,823		 Total
funds
2024
£
130,667
6,850
137,517
1,488
116,069
117,557
19,960
15,674
35,634
498,189
35,634
533,823		 Total
funds
2023
£
131,251
5,775
137,026
1,536
94,941
96,477
40,549
(12,040)
28,509
469,680
28,509
498,189

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 12 to 21 form part of these financial statements.

Page 10

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

BALANCE SHEET AS AT 31 MARCH 2024

2024 2024 2023
Note £ £
Fixed assets
Investments 12 199,044 191,492
199,044 191,492
Current assets
Debtors 13 - 2,799
Cash at bank and in hand 347,353 312,278
347,353 315,077
Creditors: amounts falling due within one year 14 (12,574) (8,380)
Net current assets 334,779 306,697
Total assets less current liabilities 533,823 498,189
Total net assets 533,823 498,189
Charity funds
Designated funds 15 199,044 275,492
General funds 15 334,779 222,697
Total unrestricted funds 15 533,823 498,189
Total funds 533,823 498,189

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

................................................

Dr J Ashcroft

Trustee

Date: 30-Jan-2025

The notes on pages 12 to 21 form part of these financial statements.

Page 11

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the defination of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Page 12

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as ‘Gains/(Losses) on investments’ in the Statement of Financial Activities.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

Page 13

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

Donations
Total 2023		 Unrestricted
funds
2024
£
130,667
131,251		 Total
funds
2024
£
130,667
131,251		 Total
funds
2023
£
131,251

4. Investment income

Income from listed investments
Interest receivable
Total 2023		 Unrestricted
funds
2024
£
5,366
1,484
6,850
5,775		 Total
funds
2024
£
5,366
1,484
6,850
5,775		 Total
funds
2023
£
5,351
424
5,775

Page 14

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

5. Investment management costs

Investment management fees
Total 2023		 Unrestricted
funds
2024
£
1,488
1,536		 Total
funds
2024
£
1,488
1,536		 Total
funds
2023
£
1,536

6. Analysis of grants

Bursaries granted
Total 2023		 Grants to
Individuals
2024
£
6,000
7,666		 Total
funds
2024
£
6,000
7,666		 Total
funds
2023
£
7,666

7. Analysis of expenditure on charitable activities

Summary by fund type

Forum expenses
Website costs
Bank charges
Staff costs (see note 10)
Accountancy (see note 9)
Total 2023		 Unrestricted
funds
2024
£
69,941
3,422
2,094
37,132
3,480
116,069
94,941		 Total
2024
£
69,941
3,422
2,094
37,132
3,480
116,069
94,941		 Total
2023
£
45,907
13,445
3,333
29,976
2,280
94,941

Page 15

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

8. Analysis of expenditure by activities

Forum expenses
Website costs
Service charges
Staff costs (see note 10)
Accountancy (see note 9)
Total 2023		 Activities
undertaken
directly
2024
£
63,941
3,422
2,094
-
-
69,457
55,019		 Grant
funding of
activities
2024
£
6,000
-
-
-
-
6,000
7,666		 Support
costs
2024
£
-
-
-
37,132
3,480
40,612
32,256		 Total
funds
2024
£
69,941
3,422
2,094
37,132
3,480
116,069
94,941		 Total
funds
2023
£
45,907
13,445
3,333
29,976
2,280
94,941

9. Independent examiner's remuneration

2024 2023
£ £
Fees payable to the Company independent examiner for the independent
examination of the Company's annual accounts 3,480 2,280

10. Staff costs

2024
£
Wages and salaries
36,357
Pension costs
775
37,132
The average number of persons employed by the Charity during the year was as follows:		 2023
£
29,049
927
29,976
2024 2023
No. No.
Administration 1 1

Page 16

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

10. Staff costs (continued)

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL) .

During the year ended 31 March 2024, expenses totalling £ 1,604 were reimbursed to 10 Trustees (2023 - £933 to 9 Trustees).

12. Fixed asset investments

Cost or valuation
At 1 April 2023
Additions
Disposals
Revaluations
Transfers
Management fees
Dividend and interest income
At 31 March 2024
Net book value
At 31 March 2024
At 31 March 2023		 Listed
investments
£
187,543
13,843
(18,006)
15,364
-
-
-
198,744
198,744
187,543		 Cash
portfolio
£
3,949
(13,843)
18,316
-
(12,000)
(1,488)
5,366
300
300
3,949		 Total
£
191,492
-
310
15,364
(12,000)
(1,488)
5,366
199,044
199,044
191,492

Page 17

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

13. Debtors

Due within one year
Other debtors		 2024
£
-
-		 2023
£
2,799
2,799

14. Creditors: Amounts falling due within one year

Trade creditors
Other taxation and social security
Pension fund loan payable
Other creditors
Accruals and deferred income		 2024
£
-
1,544
314
7,236
3,480
12,574		 2023
£
6,150
-
130
-
2,100
8,380

Page 18

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds

Statement of funds - current year
Designated funds
Michael Morley Investment Fund
General funds
General Funds
Total Unrestricted funds		 Balance at 1
April 2023
£
275,492
222,697
498,189		 Income
£
5,366
132,151
137,517		 Expenditure
£
(1,488)
(116,069)
(117,557)		 Transfers
in/out
£
(96,000)
96,000
-		 Gains/
(Losses)
£
15,674
-
15,674		 Balance at 31
March 2024
£
199,044
334,779
533,823

Page 19

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

15.
Statement of funds (continued)
Statement of funds - prior year
Designated funds
Michael Morley Investment Fund
General funds
General Funds
Total Unrestricted funds		 Balance at
1 April 2022
£
283,717
185,963
469,680		 Income
£
5,351
131,675
137,026		 Expenditure
£
(1,536)
(94,941)
(96,477)		 Gains/
(Losses)
£
(12,040)
-
(12,040)		 Balance at
31 March
2023
£
275,492
222,697
498,189

The designated fund is used to hold the Charity's investments and generate income.

Page 20

Docusign Envelope ID: A381FBDD-D234-415C-A4D0-1FC7E5596429

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

16. Analysis of net assets between funds

Analysis of net assets between funds - current period

Fixed asset investments
Current assets
Creditors due within one year
Total		 Unrestricted
funds
2024
£
199,044
347,353
(12,574)
533,823		 Total
funds
2024
£
199,044
347,353
(12,574)
533,823

Analysis of net assets between funds - prior period

Fixed asset investments
Current assets
Creditors due within one year
Total		 Unrestricted
funds
2023
£
191,492
315,077
(8,380)
498,189		 Total
funds
2023
£
191,492
315,077
(8,380)
498,189

17. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2024.

Page 21